Cytogenetic status and oxidative stress parameters in patients with thyroid diseases

Stewart, 2016, Cancer prevention as part of precision medicine: plenty to be done, Carcinogenesis, 37, 2, 10.1093/carcin/bgv166

Ferlay, 2013, GLOBOCAN 2012. v1.0, cancer incidence and mortality worldwide: IARC cancer base No . 11, lyon, fr, Int. Agency Res. Cancer

Wu, 2012, Cancer incidence among adolescents and young adults in urban shanghai, 1973–2005, PLoS One., 7, e42607, 10.1371/journal.pone.0042607

Jung, 2013, Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010, Cancer Res. Treat., 45, 1, 10.4143/crt.2013.45.1.1

Blomberg, 2012, Thyroid cancer in Denmark 1943–2008, before and after iodine supplementation, Int J. Cancer., 131, 2360, 10.1002/ijc.27497

Croatian National Cancer Registry, Cancer incidence in Croatia in 2012, 2014.

Kirsch-Volders, 2014, Commentary: critical questions, misconceptions and a road map for improving the use of the lymphocyte cytokinesis-block micronucleus assay for in vivo biomonitoring of human exposure to genotoxic chemicals—A HUMN project perspective, Mutat Res. Mutat. Res., 759, 49, 10.1016/j.mrrev.2013.12.001

Domijan, 2007, The involvement of oxidative stress in ochratoxin A and fumonisin B1 toxicity in rats, Mol. Nutr. Food Res., 51, 1147, 10.1002/mnfr.200700079

Kim, 2013, Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer, Clin. Endocrinol. (Oxf)., 78, 134, 10.1111/j.1365-2265.2012.04506.x

De Pergola, 2013, Obesity as a major risk factor for cancer, J. Obes., 2013, 291546, 10.1155/2013/291546

Xhaard, 2015, Anthropometric risk factors for differentiated thyroid cancer in young men and women from Eastern France: a case-control study, Am. J. Epidemiol., 182, 202, 10.1093/aje/kwv048

Bonassi, 2008, Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries, Carcinogenesis, 29, 1178, 10.1093/carcin/bgn075

Bonassi, 2007, An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans, Carcinogenesis, 28, 625, 10.1093/carcin/bgl177

Bonassi, 2011, Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies, Mutagenesis, 26, 93, 10.1093/mutage/geq075

Bonassi, 2005, Human population studies with cytogenetic biomarkers: review of the literature and future prospectives, Environ. Mol. Mutagen., 45, 258, 10.1002/em.20115

Smith, 2003, DNA damage and breast cancer risk, Carcinogenesis, 24, 883, 10.1093/carcin/bgg037

Santos, 2010, Takahashi, Basal levels of DNA damage detected by micronuclei and comet assays in untreated breast cancer patients and healthy women, Clin. Exp. Med., 10, 87, 10.1007/s10238-009-0079-4

Lou, 2007, Investigating the genetic instability in the peripheral lymphocytes of 36 untreated lung cancer patients with comet assay and micronucleus assay, Mutat. Res., 617, 104, 10.1016/j.mrfmmm.2007.01.004

Vasavi, 2010, Assessment of genetic damage in inflammatory, precancerous, and cancerous pathologies of the esophagus using the comet assay, Genet Test. Mol. Biomarkers., 14, 477, 10.1089/gtmb.2010.0006

Sigurdson, 2011, Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Carcinogenesis, 32, 69, 10.1093/carcin/bgq204

Erdamar, 2010, Increased lipid peroxidation and impaired enzymatic antioxidant defense mechanism in thyroid tissue with multinodular goiter and papillary carcinoma, Clin. Biochem., 43, 650, 10.1016/j.clinbiochem.2010.02.005

Krohn, 2007, Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors, Nat. Clin. Pract. Endocrinol. Metab., 3, 713, 10.1038/ncpendmet0621

Fortunato, 2014, Sexual dimorphism and thyroid dysfunction: a matter of oxidative stress?, J. Endocrinol., 221, R31, 10.1530/JOE-13-0588

Xing, 2013, Molecular pathogenesis and mechanisms of thyroid cancer, Nat. Rev. Cancer., 13, 184, 10.1038/nrc3431

Kondo, 2007, Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas, Hum. Pathol., 38, 1810, 10.1016/j.humpath.2007.04.014

Nikiforov, 2011, Molecular genetics and diagnosis of thyroid cancer, Nat. Rev. Endocrinol., 7, 569, 10.1038/nrendo.2011.142

Lee, 2005, High prevalence of c-RET expression in papillary thyroid carcinomas from the Korean population, Thyroid, 15, 259, 10.1089/thy.2005.15.259

De Groot, 2006, RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors, Endocr. Rev., 27, 535, 10.1210/er.2006-0017

Weeraratna, 2012, RAF around the edges − the paradox of BRAF inhibitors, N. Engl. J. Med., 366, 271, 10.1056/NEJMe1111636

Zambon, 2013, BRAF as a therapeutic target: a patent review (2006–2012), Expert Opin. Ther. Pat., 23, 155, 10.1517/13543776.2013.741593

Girotti, 2015, Paradox-Breaking RAF inhibitors that also target SRC are effective in drug-Resistant BRAF mutant melanoma, Cancer Cell., 27, 85, 10.1016/j.ccell.2014.11.006

Jung, 2014, The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations, J. Clin. Endocrinol. Metab., 99, E276, 10.1210/jc.2013-2503

Nikiforova, 2013, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer, J. Clin. Endocrinol. Metab., 98, E1852, 10.1210/jc.2013-2292